$174.7M in CY2024 Part D spend8.1M claims · 2.6M beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Oxybutynin used for?
Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Is there a generic for Oxybutynin?
Yes. 39 ANDAs filed at FDA, 21 generic manufacturers currently shipping.
How much does my plan pay for Oxybutynin?
Across 329 Part D plans, Oxybutynin averages $0.046/unit (NADAC). Lowest available: $0.032/unit. Highest in distribution: $0.048/unit.
Is Oxybutynin on the FDA shortage list?
Oxybutynin has been discontinued by its manufacturer(s).
7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.